Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Peter Maag
AddedMar 31, 2024
UpdatedJun 28, 2026
Peter Maag

Peter Maag

Board Member, Phoenix Pharmahandel

Crunchbase

Peter Maag's Career

Phoenix Pharmahandel
Phoenix Pharmahandel

Mannheim, Baden-Württemberg, DE

Board Member· Board
Miromatrix Medical
Miromatrix Medical

Eden Prairie, MN, US

Board Member· Board
CareDx
CareDx

Brisbane, CA, US

Board Member· Board
Kyverna Therapeutics
Kyverna Therapeutics

Emeryville, CA, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Peter Maag's Career

Phoenix Pharmahandel
Phoenix Pharmahandel
Public39k1994Mannheim, Baden-Württemberg, DE
Board Member· Board

Leadership at Phoenix Pharmahandel

Carsten SauerlandCarsten SauerlandBoard Member
Sven SeidelSven SeidelCEO
Mark GoodwinMark GoodwinCo-Founder
Chris LucasChris LucasCo-Founder
Ludwig MerckleLudwig MerckleBoard Member
Lorenz NaegerLorenz NaegerBoard Member
Miromatrix Medical
Miromatrix Medical

Eden Prairie, MN, US

Board Member· Board
CareDx
CareDx
Public$574.9M7701999Brisbane, CA, US
Board Member· Board

Recent news

Calo raises $25 million to expand its ready-to-eat meal service beyond the Middle EastTechCrunch · 2024

Leadership at CareDx

Brook ByersBrook ByersBoard Member
Jay WohlgemuthJay WohlgemuthFounder
Ralph SnydermanRalph SnydermanBoard Member
Michael GoldbergMichael GoldbergBoard Member
Grace ColónGrace ColónBoard Member

Similar to CareDx

SynapDxSynapDxLexington, MA, USDiagnostic Testsest. 2010SynapDxLexington, MA, US · est. 2010

SynapDX: Pioneering early autism detection through blood-based diagnostic tests.

Series B · $32.4M11
DxNADxNASt. George, UT, USDiagnostic TestsDxNASt. George, UT, US

DxNA LLC, a Utah-based medical organization, develops affordable, rapid molecular diagnostic tools, focusing on infectious diseases for underserved hospitals and clinics.

Angel · $6.6M19
Kyverna Therapeutics
Kyverna Therapeutics
Series B$170M922018Emeryville, CA, US
CEO· C-Suite · Management

Leadership at Kyverna Therapeutics

Brian KotzinBrian KotzinBoard Member
Beth SeidenbergBeth SeidenbergBoard Member
Dan SpiegelmanDan SpiegelmanBoard Member
Jeffrey GreveJeffrey GreveFounder
Mark GenoveseMark GenoveseBoard Member
Fred E. CohenFred E. CohenBoard Member

Peter Maag's Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Peter Maag

Ian ClarkIan ClarkBoard Member · Kyverna TherapeuticsMichael KauffmanMichael KauffmanCEO · Nereid TherapeuticsJeff ForringerJeff ForringerCEO · Kyber Data ScienceRemo Moomiaie-Qajar M.D.Remo Moomiaie-Qajar M.D.Co-Founder & CEO · Cytonus TherapeuticsJeff McDonaldJeff McDonaldCo-Founder & CEO · Kythera Labs